Nine open-end mutual funds out of a select screen have 20% or more of their assets in a single stock, and have suffered as a result, TheStreet.com reports. The website screened for funds with minimum initial investments of $50,000 or less and that aren’t structured as funds-of-funds.

With 20.8% of its assets invested in Amgen, the ProFunds Biotech Ultra Sector Fund has delivered a negative 15.62% return over the past year, primarily due to Amgen’s 23% decline.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.